国药一致：前三季度净利润9.57亿元，同比下降10.18%

Core Viewpoint - The company reported a total operating revenue of 55.124 billion yuan for the first three quarters, representing a year-on-year decrease of 2.38% and a net profit of 0.957 billion yuan, down 10.18% year-on-year, indicating challenges in the current external environment [1] Group 1 - The company will focus on "increasing revenue, reducing costs, and improving efficiency" as key directions to navigate the complex external environment [1] - The company aims to accelerate digital transformation, deepen organizational change, and implement refined management practices [1] - The company plans to adjust its business structure to continuously enhance operational quality and risk resistance capabilities for steady development [1]